Afatinib Treatment for Advanced Mixed Non-small Cell Lung Cancer with CRISPLD2-NRG1 Fusion:A Case Report and Literature Review

VernacularTitle:罕见CRISPLD2-NRG1融合突变晚期混合型非小细胞肺癌1例并文献复习
Author: CHEN CHUNMEI ¹ ; YU YANG ; HUANG MEIJUAN
Author Information

1. 610073 成都,成都市成飞医院呼吸与危重症医学科
Keywords: Lung neoplasms; Afatinib; CRISPLD2-NRG1 fusion mutation
From: Chinese Journal of Lung Cancer 2024;27(5):399-404
CountryChina
Language:Chinese
Abstract: Lung cancer is the most common malignant disease and the leading cause of cancer death in China.Non-small cell lung cancer(NSCLC)accounts for over 80％of all lung cancers,and the probability of NSCLC gene mutations is high,with a wide variety of types.With the development of next-generation sequencing(NGS)detection technology,more and more patients with rare fusion gene mutations are detected.Neuregulin 1(NRG1)gene is a rare oncogenic driver that can lead to activation of human epidermal growth factor receptor 3(Her3/ErbB3)mediated pathway,resulting in tumor forma-tion.In this article,we reported a case of mixed NSCLC with CRISPLD2-NRG1 fusion detected by RNA-based NGS,who re-sponsed to Afatinib well after 1 month of treatment,and magnetic resonance imaging(MRI)showed shrinkage of intracranial lesions.Meanwhile,we also compiled previously reported NSCLC patients with NRG1 rare gene fusion mutation,in order to provide effective references for clinical diagnosis and treatment.